» Articles » PMID: 33911034

ADAM9 Enhances Th17 Cell Differentiation and Autoimmunity by Activating TGF-β1

Overview
Specialty Science
Date 2021 Apr 29
PMID 33911034
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The a disintegrin and metalloproteinase (ADAM) family of proteinases alter the extracellular environment and are involved in the development of T cells and autoimmunity. The role of ADAM family members in Th17 cell differentiation is unknown. We identified ADAM9 to be specifically expressed and to promote Th17 differentiation. Mechanistically, we found that ADAM9 cleaved the latency-associated peptide to produce bioactive transforming growth factor β1, which promoted SMAD2/3 phosphorylation and activation. A transcription factor inducible cAMP early repressor was found to bind directly to the promoter and to promote its transcription. -deficient mice displayed mitigated experimental autoimmune encephalomyelitis, and transfer of -deficient myelin oligodendrocyte globulin-specific T cells into mice failed to induce disease. At the translational level, an increased abundance of ADAM9 levels was observed in CD4 T cells from patients with systemic lupus erythematosus, and ADAM9 gene deletion in lupus primary CD4 T cells clearly attenuated their ability to differentiate into Th17 cells. These findings revealed that ADAM9 as a proteinase provides Th17 cells with an ability to activate transforming growth factor β1 and accelerates its differentiation, resulting in aberrant autoimmunity.

Citing Articles

ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1.

Meng Q, Bao D, Liu S, Huang J, Guo M, Dai B Mol Med. 2024; 30(1):269.

PMID: 39716051 PMC: 11665244. DOI: 10.1186/s10020-024-01047-8.


Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells, Which Enhances Transforming Growth Factor β1 Activation and Promotes Tissue Fibrosis in Patients With Lupus Nephritis.

Umeda M, Karino K, Satyam A, Yoshida N, Hisada R, Bhargava R Arthritis Rheumatol. 2024; 77(2):180-189.

PMID: 39279154 PMC: 11785507. DOI: 10.1002/art.42987.


LncRNA NEAT1 targets miR-125/ADAM9 mediated NF-κB pathway in inflammatory response of rosacea.

Xu S, Dong W Skin Res Technol. 2024; 30(7):e13630.

PMID: 38988131 PMC: 11237170. DOI: 10.1111/srt.13630.


A Disintegrin and metalloproteinase carves T cell abnormalities and pathogenesis in systemic lupus erythematosus.

Umeda M, Satyam A, Yoshida N, Kawakami A Clin Immunol. 2024; 262:110168.

PMID: 38458301 PMC: 11009040. DOI: 10.1016/j.clim.2024.110168.


Consequences of Amyloid-β Deficiency for the Liver.

Buniatian G, Schwinghammer U, Tremmel R, Cynis H, Weiss T, Weiskirchen R Adv Sci (Weinh). 2024; 11(18):e2307734.

PMID: 38430535 PMC: 11095235. DOI: 10.1002/advs.202307734.


References
1.
Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro P, Blobel C . ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol. 2009; 29(10):2694-703. PMC: 2682031. DOI: 10.1128/MCB.01460-08. View

2.
McGeachy M, Bak-Jensen K, Chen Y, Tato C, Blumenschein W, Mcclanahan T . TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007; 8(12):1390-7. DOI: 10.1038/ni1539. View

3.
Yoshida N, Comte D, Mizui M, Otomo K, Rosetti F, Mayadas T . ICER is requisite for Th17 differentiation. Nat Commun. 2016; 7:12993. PMC: 5056420. DOI: 10.1038/ncomms12993. View

4.
Bridges L, Bowditch R . ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity. Curr Pharm Des. 2005; 11(7):837-47. DOI: 10.2174/1381612053381747. View

5.
Roychaudhuri R, Hergrueter A, Polverino F, Laucho-Contreras M, Gupta K, Borregaard N . ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury. J Immunol. 2014; 193(5):2469-82. PMC: 4134955. DOI: 10.4049/jimmunol.1303370. View